Robert Wills - 23 Feb 2024 Form 4 Insider Report for Oncternal Therapeutics, Inc. (ONCT)

Role
Director
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Issuer symbol
ONCT
Transactions as of
23 Feb 2024
Transactions value $
-$8,859
Form type
4
Filing time
27 Feb 2024, 17:02:41 UTC
Previous filing
26 Jan 2024
Next filing
22 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONCT Common Stock Sale -$8.86K -980 -100% $9.04 0 23 Feb 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock were sold directly to another director of the Issuer, David F. Hale, and an affiliated entity of Mr. Hale in a private sale. The price per share was based on the closing price of the Issuer's common stock on February 23, 2024.

Remarks:

The number of shares of common stock in this form have been adjusted to reflect the Issuer's 1-for-20 reverse stock split effective as of January 8, 2024.